Human Longevity Inc., USA
Dr. Wei-Wu He is currently the Chairman and CEO of Human Longevity Inc. Prior to HLI, Dr. He was the CEO of OriGene Technologies, Inc.(merged with VcanBio. China A share:600645). He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 100 biotech companies throughout his career, many of them have been acquired or listed on public market. Dr. He was the founder and served as Chairman of many biotechnology companies such as Genetron Health, Juventas Cell Therapy, etc.In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences ($4 Billion acquisition by GSK), and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 30 issued patents. Dr. He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.
Dr. Wei-Wu He is currently the Chairman and CEO of Human Longevity Inc. Prior to HLI, Dr. He was the CEO of OriGene Technologies, Inc.(merged with VcanBio. China A share:600645). He also is the founder and General Partner of Emerging Technology Partners, LLC (ETP), a life sciences focused venture fund established since 2000. Dr. He has been involved in founding or funding over 100 biotech companies throughout his career, many of them have been acquired or listed on public market. Dr. He was the founder and served as Chairman of many biotechnology companies such as Genetron Health, Juventas Cell Therapy, etc.In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences ($4 Billion acquisition by GSK), and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic. Dr. He is an author to more than 30 research publications and inventor of over 30 issued patents. Dr. He received his PhD in Molecular Biology from Baylor College of Medicine and received an MBA degree from the Wharton School.